vs
CHEMUNG FINANCIAL CORP（CHMG）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是CHEMUNG FINANCIAL CORP的1.3倍（$30.3M vs $23.8M），CHEMUNG FINANCIAL CORP净利率更高（32.5% vs -221.3%，领先253.8%），REGENXBIO Inc.同比增速更快（43.0% vs 20.3%），CHEMUNG FINANCIAL CORP自由现金流更多（$43.8M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.2%）
切芒金融旗下的切芒运河信托公司是一家总部位于纽约州埃尔迈拉的纽约州特许信托公司，其前身是1833年成立的公开上市银行，深耕本土金融信托业务，为当地及周边地区客户提供专业的金融服务。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CHMG vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.3倍
$23.8M
营收增速更快
RGNX
高出22.7%
20.3%
净利率更高
CHMG
高出253.8%
-221.3%
自由现金流更多
CHMG
多$96.6M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.8M | $30.3M |
| 净利润 | $7.7M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 46.1% | -190.0% |
| 净利率 | 32.5% | -221.3% |
| 营收同比 | 20.3% | 43.0% |
| 净利润同比 | 30.9% | -31.2% |
| 每股收益（稀释后） | $1.61 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CHMGRGNX
| Q4 25 | $23.8M | $30.3M | ||
| Q3 25 | $28.8M | $29.7M | ||
| Q2 25 | $10.1M | $21.4M | ||
| Q1 25 | $25.7M | $89.0M | ||
| Q4 24 | $25.9M | $21.2M | ||
| Q3 24 | $24.3M | $24.2M | ||
| Q2 24 | $23.4M | $22.3M | ||
| Q1 24 | $23.7M | $15.6M |
净利润CHMGRGNX
| Q4 25 | $7.7M | $-67.1M | ||
| Q3 25 | $7.8M | $-61.9M | ||
| Q2 25 | $-6.5M | $-70.9M | ||
| Q1 25 | $6.0M | $6.1M | ||
| Q4 24 | $5.9M | $-51.2M | ||
| Q3 24 | $5.7M | $-59.6M | ||
| Q2 24 | $5.0M | $-53.0M | ||
| Q1 24 | $7.0M | $-63.3M |
毛利率CHMGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CHMGRGNX
| Q4 25 | 46.1% | -190.0% | ||
| Q3 25 | 35.0% | -176.3% | ||
| Q2 25 | -87.2% | -296.3% | ||
| Q1 25 | 29.9% | 13.6% | ||
| Q4 24 | 29.0% | -242.1% | ||
| Q3 24 | 29.8% | -256.6% | ||
| Q2 24 | 26.8% | -251.3% | ||
| Q1 24 | 38.3% | -408.8% |
净利率CHMGRGNX
| Q4 25 | 32.5% | -221.3% | ||
| Q3 25 | 27.1% | -208.3% | ||
| Q2 25 | -63.9% | -331.8% | ||
| Q1 25 | 23.4% | 6.8% | ||
| Q4 24 | 29.8% | -241.3% | ||
| Q3 24 | 23.5% | -246.3% | ||
| Q2 24 | 21.3% | -237.7% | ||
| Q1 24 | 29.7% | -405.4% |
每股收益（稀释后）CHMGRGNX
| Q4 25 | $1.61 | $-1.30 | ||
| Q3 25 | $1.62 | $-1.20 | ||
| Q2 25 | $-1.35 | $-1.38 | ||
| Q1 25 | $1.26 | $0.12 | ||
| Q4 24 | $1.24 | $-0.99 | ||
| Q3 24 | $1.19 | $-1.17 | ||
| Q2 24 | $1.05 | $-1.05 | ||
| Q1 24 | $1.48 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $50.1M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $254.7M | $102.7M |
| 总资产 | $2.7B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CHMGRGNX
| Q4 25 | $50.1M | $230.1M | ||
| Q3 25 | $107.6M | $274.2M | ||
| Q2 25 | $320.1M | $323.3M | ||
| Q1 25 | $53.4M | $267.9M | ||
| Q4 24 | $47.0M | $234.7M | ||
| Q3 24 | $80.4M | $255.5M | ||
| Q2 24 | $70.2M | $290.4M | ||
| Q1 24 | $94.9M | $338.7M |
总债务CHMGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $99.1M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CHMGRGNX
| Q4 25 | $254.7M | $102.7M | ||
| Q3 25 | $245.3M | $161.5M | ||
| Q2 25 | $235.0M | $213.7M | ||
| Q1 25 | $228.3M | $274.2M | ||
| Q4 24 | $215.3M | $259.7M | ||
| Q3 24 | $220.7M | $301.4M | ||
| Q2 24 | $201.2M | $348.3M | ||
| Q1 24 | $197.1M | $390.7M |
总资产CHMGRGNX
| Q4 25 | $2.7B | $453.0M | ||
| Q3 25 | $2.7B | $525.2M | ||
| Q2 25 | $2.9B | $581.0M | ||
| Q1 25 | $2.8B | $490.9M | ||
| Q4 24 | $2.8B | $466.0M | ||
| Q3 24 | $2.8B | $519.1M | ||
| Q2 24 | $2.8B | $569.4M | ||
| Q1 24 | $2.8B | $629.2M |
负债/权益比CHMGRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $43.8M | $-52.8M |
| 自由现金流率自由现金流/营收 | 183.7% | -174.0% |
| 资本支出强度资本支出/营收 | 7.1% | 1.7% |
| 现金转化率经营现金流/净利润 | 5.88× | — |
| 过去12个月自由现金流最近4个季度 | $71.9M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CHMGRGNX
| Q4 25 | $45.5M | $-52.3M | ||
| Q3 25 | $12.2M | $-56.0M | ||
| Q2 25 | $9.7M | $-49.3M | ||
| Q1 25 | $7.2M | $33.6M | ||
| Q4 24 | $29.8M | $-31.6M | ||
| Q3 24 | $9.2M | $-40.5M | ||
| Q2 24 | $6.5M | $-45.5M | ||
| Q1 24 | $7.9M | $-55.5M |
自由现金流CHMGRGNX
| Q4 25 | $43.8M | $-52.8M | ||
| Q3 25 | $11.8M | $-56.5M | ||
| Q2 25 | $9.4M | $-49.7M | ||
| Q1 25 | $6.9M | $32.6M | ||
| Q4 24 | $26.2M | $-32.7M | ||
| Q3 24 | $8.6M | $-40.9M | ||
| Q2 24 | $5.5M | $-46.0M | ||
| Q1 24 | $7.9M | $-56.0M |
自由现金流率CHMGRGNX
| Q4 25 | 183.7% | -174.0% | ||
| Q3 25 | 41.1% | -189.9% | ||
| Q2 25 | 92.9% | -232.8% | ||
| Q1 25 | 26.7% | 36.6% | ||
| Q4 24 | 101.2% | -154.2% | ||
| Q3 24 | 35.2% | -168.9% | ||
| Q2 24 | 23.4% | -206.2% | ||
| Q1 24 | 33.1% | -358.5% |
资本支出强度CHMGRGNX
| Q4 25 | 7.1% | 1.7% | ||
| Q3 25 | 1.4% | 1.7% | ||
| Q2 25 | 3.6% | 1.8% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 14.0% | 5.1% | ||
| Q3 24 | 2.5% | 1.3% | ||
| Q2 24 | 4.4% | 2.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率CHMGRGNX
| Q4 25 | 5.88× | — | ||
| Q3 25 | 1.57× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.19× | 5.53× | ||
| Q4 24 | 5.04× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.30× | — | ||
| Q1 24 | 1.13× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CHMG
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
